Transmission of vaccinia virus after smallpox vaccination is a concern. We conducted a prospective examination of the protection afforded by vaccination-site bandages in recently vaccinated individuals. After smallpox vaccination, inoculation sites were covered with 2 occlusive dressings. Site assessment and bandage changes occurred every 3-5 days until the site was healed. At each visit, specimens from the vaccination site, outer dressing surface, and contralateral hand were obtained for vaccinia culture. For 148 vaccinated subjects, vaccinia was detected from vaccination lesions of every subject on several occasions. Only 6 (0.65%) of 918 dressing (95% CI, 0.24%-1.4%) and 2 (0.22%) of 926 hand (95% CI, 0.03%-0.78%) specimens tested positive for vaccinia. The mean number of bandage changes was 9.6 (95% CI, 9.17-10.0). Vaccinia autoinoculation did not occur. The rate of vaccinia recovery outside occlusive bandages covering smallpox vaccination sites was remarkably low, suggesting excellent protection against inadvertent transmission.
cerns of possible transmission of vaccinia virus to atrisk patients [2] .
Smallpox vaccination entails the induction of a localized skin infection from live vaccinia virus, a related poxvirus, to confer immunity to smallpox (variola). Spread of vaccinia virus occurs predominantly through contact. Individuals may transmit virus from their vaccination sites, potentially leading to substantial morbidity and even mortality in immunocompromised patients or those with eczema [3] . The risk of nosocomial transmission of vaccinia from a vaccinated health care worker has been thought by some to pose a greater risk than the possibility of smallpox release [4] .
Precautions to reduce the potential spread of vaccinia from vaccinated individuals include application of an occlusive bioadhesive dressing over the lesion site and careful attention to dressing care and hand hygiene. The recent civilian and military vaccination campaigns reassuringly illustrated the efficacy of this approach: there were rare cases of secondary vaccinia transmission [5, 6] . In a clinical investigation that complements the practical experience seen in these vaccination campaigns, we conducted a prospective surveillance study by using viral culture data to investigate the recovery Household or sexual contacts with any of the following conditions or factors: history of or concurrent eczema, history of exfoliative skin disorders, history of the immunosuppressive conditions noted above, ongoing pregnancy, or children aged !12 months of vaccinia from vaccination sites covered by occlusive bandages.
PATIENTS, MATERIALS, AND METHODS
Study subjects. Subjects for this study were recruited from individuals enrolled at a study site (Vanderbilt University; Nashville, TN) participating in a multicenter, double-blind, randomized clinical trial investigating the safety and efficacy of 3 different dilutions of the Aventis Pasteur smallpox vaccine (APSV), a liquid formulation of calf lymph origin smallpox vaccine derived from the New York Board of Health vaccinia strain and maintained frozen at Ϫ20ЊC. In this trial, healthy vaccinia-naive subjects aged 18-32 years were recruited; those who met appropriate screening qualifications and who did not meet any of the exclusion criteria for vaccination (table 1) were enrolled. All vaccinated subjects were eligible for participation in the prospective culture surveillance study, which was conducted under a separate consent process. Both the randomized trial and the surveillance study were approved by the Vanderbilt University Institutional Review Board; all subjects consented to both studies. Human experimentation guidelines of the US Department of Health and Human Services and Vanderbilt University were followed in the conduct of this research. Vaccination methods and follow-up. As a part of the safety and efficacy trial, eligible subjects were randomized to receive 1 of 3 strengths of APSV (undiluted or dilutions of 1:5 or 1: 10). Frozen vaccine was reconstituted with diluent containing glycerin, phenol, and sterile water and was administered in the deltoid area via scarification by 15 punctures with a bifurcated needle, as described elsewhere [1] . Vaccination sites were covered with 2 occlusive bandages, an initial waterproof gauzeimpregnated transparent bandage (Opsite Post-Op; Smith & Nephew) and an outer waterproof semipermeable bandage (Tegaderm; 3M HealthCare). Subjects were seen in clinic every 3-5 days for scheduled dressing changes, assessment of vaccine response, and adverse event evaluation. These dressing changes were performed by the study staff until the vaccination site was well scabbed, which usually occurred several weeks after vaccination. Subjects were taught how to remove old dressings and apply new ones in case an unscheduled dressing change was needed before the next clinic visit. Sterile gloves and clean bandages were provided to each volunteer. Subjects were instructed to place soiled bandages in biohazard bags provided by study staff and to dispose of the bags at the next scheduled clinic visit. Subjects were also repeatedly counseled at each visit to avoid manipulation of the vaccination site and dressing and to use gloves and thoroughly wash hands after any dressing manipulation. There were no restrictions on work activities after vaccination, in accordance with the US Centers for Disease Control and Prevention guidelines [7] . At all follow-up visits, each subject was assessed by history, symptom report, and physical examination for evidence of autoinoculation. Because of study constraints, close contacts of subjects were not actively examined for evidence of secondary transmission.
Culture methods. Samples for viral culture were obtained from each subject at each scheduled follow-up visit, beginning with the first visit 3-5 days after vaccination. We used cottontipped swabs to obtain specimens from the palmar surface of the index finger on the hand contralateral to the dressing site (hand sample), from the outer surface of the outer dressing before bandage removal (dressing sample), and from the vaccination site lesion (lesion sample) at each visit. Before the hand and dressing samples were obtained, the swabs were moistened with sterile saline. However, a dry swab was used to obtain the lesion sample to avoid disruption of the healing process. Samples were obtained at each clinic visit until the lesion was well scabbed without drainage and no longer required dressing. Study staff changed gloves between the removal of the old bandage and the placement of the new bandage. Samples of the vaccination lesions were obtained at day 28 after vaccination for all subjects, regardless of the lesion status. In those subjects whose sites had not yet healed, dressing and hand samples were also obtained for culture. By means of methods described elsewhere [8] , specimens were directly inoculated into 1 mL of standard Hank viral transport media and frozen at Ϫ70ЊC for batch processing. It was expected that vaccinia would be recovered from a majority of the lesion specimens, because these cultures were obtained from direct contact with the vaccinia pustule. All lesion specimens were inoculated undiluted and at dilutions of 1:10, 1:100, and 1:1000 in triplicate directly onto plates coated with BSC-40 cells (African green monkey kidney) and washed with sterile PBS. After incubation, cells were fixed with formalin and stained with crystal violet to visualize the presence of characteristic vaccinia plaques. Plates without plaque formation at 2 days were considered to be negative for vaccinia. Quantitative titers for positive specimens were expressed as the average of the triplicate counts in log 10 plaque-forming units (pfu) per milliliter. Specimens with titers that were too high to quantify at initial dilution underwent further dilutions up to 1:100,000.
Because vaccinia recovery was expected to be low from the hand and bandage specimens, undiluted specimens were screened for the presence of vaccinia before performing triplicate dilutions. Specifically, 0.2 mL of each hand and dressing specimen was inoculated undiluted into tubes coated with BSC-40 cells. The presence of distinctive cytopathic effect (CPE) [9] was assessed every 48-72 h. Tubes without CPE at 10 days were considered to be negative for vaccinia. Positive hand and bandage specimens were then titrated for the lesion specimens, as described above. As the study progressed, it became apparent that all vaccinia-positive hand and bandage specimens that exhibited CPE within 10 days after inoculation also developed viral plaques within 48 h when inoculated on the titration plates. Therefore, to reduce the screening time from 10 to 2 days, midway through the study, undiluted hand and dressing specimens were inoculated directly onto the tissue plates and screened for pfu. Specimens with plaque formation at 48 h were then titrated as described above for the lesion specimens.
Clinical data collection. Demographic information (age and sex) was obtained at the start of the study. At each followup visit, data on the number of dressing changes performed by the subject since the previous clinic visit (unscheduled changes) and on concurrent illnesses were collected. Data were abstracted from charts at study completion for information on adverse local and systemic findings after vaccination, including the development of fever (temperature, у38.4ЊC), local axillary lymphadenopathy, and focal satellite lesions of vaccinia around the initial site.
Analysis
RESULTS
All 148 volunteers enrolled in the primary clinical trial at Vanderbilt University participated in the surveillance study. The mean age (‫ע‬SD) of the cohort was 23.6 ‫ע‬ 3.65 years; 56% of the subjects were female. The cohort consisted of health care workers, students enrolled in area colleges and universities, and other community members. All subjects completed follow-up. The specific dilution of vaccine received was evenly distributed among the 3 potencies (undiluted vaccine, 51 subjects; 1:5 dilution, 48; 1:10 dilution, 49). Subjects completed an average of 6.9 follow-up visits (95% CI, 6.79-7.10) for a mean duration of follow-up of 27.9 days (95% CI, 27.5-28.2). Bandages were changed an average of 9.6 times (95% CI, 9.17-10.0; mean number of scheduled changes, 6.9 [95% CI, 6.75-7.05]; mean number of unscheduled changes, 2.7 [95% CI, 2.30-3.08]). There was no evidence of autoinoculation of vaccinia in any subject. A total of 2843 specimens (999 lesion samples, 918 dressing samples, and 926 hand samples) were obtained (table 2) . Vaccinia was isolated from the vaccination lesions of every subject on multiple occasions (mean total number of positive lesion cultures, 5.22; 95% CI, 5.06-5.39). Peak lesion titers occurred an average 12.8 days after vaccination (95% CI, 12.3-13.3 days), with a mean peak lesion titer of 5.25 log 10 pfu/mL (95% CI, 5.13-5.38 log 10 pfu/mL; range, 2.7-7.3 log 10 pfu/mL). A typical time course of vaccinia shedding is shown in figure 1 .
Only 6 (0.65%) of 918 dressing samples (95% CI, 0.24%-1.4%) were positive for vaccinia. The range for dressing specimen titers was 0.5-2.7 log 10 pfu/mL, with a mean peak titer of 1.77 log 10 pfu/mL (95% CI, 0.82-2.71 log 10 pfu/mL). The mean time to a positive dressing culture was 10.2 days (95% CI, 6.47-15.2 days), with 5 of the 6 positive specimens obtained 7-10 days after vaccination (figure 2). Although 6 (4.1%) of 148 subjects (95% CI, 1.5%-8.6%) had 1 positive dressing specimen result, vaccinia was not recovered on a second occasion from any subject. There was no significant difference between individuals with and without a positive dressing specimen result with regard to age, sex, dilution of vaccine received, number of dressing changes (scheduled, unscheduled, and total), time to site healing, occurrence of fever or lymphadenopathy, occurrence of satellite lesions, peak lesion culture titer, mean lesion culture titer, total duration of follow-up, or total number of follow-up visits (table 3) . Rarely, subjects presented at followup without a dressing covering the site, and a dressing culture could not be obtained.
Vaccinia was recovered from only 2 (0.22%) of 926 hand specimens (95% CI, 0.03%-0.78%), each of which had been obtained from a different subject (figure 2). For one subject, vaccinia was recovered from the hand, dressing, and lesion specimens 10 days after vaccination. Virus titers at this time were 4.6 log 10 pfu/mL at the vaccination site, 2.7 log 10 pfu/mL on the outer dressing, and 1.8 log 10 pfu/mL on the hand. The other subject with a positive hand culture result had vaccinia recovered from both the hand and the lesion at 15 days after vaccination. Each sample had a titer of 1.0 log 10 pfu/mL; the results of the culture of the dressing sample at this visit were negative. Because of the small number of positive hand culture results, we were unable to perform an analysis of risk factors for retrieval of vaccinia from the hands, such as hand hygiene or number of bandage changes.
DISCUSSION
Our investigation provides contemporary viral culture surveillance confirming that the risk of inadvertent vaccinia transmission from vaccination sites covered by occlusive bandages to areas outside of the bandage is quite low. Although a direct correlation between the recovery of vaccinia on a vaccinated person's hands and cases of secondary contact spread has not been established, the extremely low rate of vaccinia recovery outside of the occlusive bandage provides great reassurance that contact transmission is unlikely.
The inadvertent transmission of vaccinia to unvaccinated individuals ("contact vaccinia") has been a particular concern for health care workers as a result of potential transmission to immunosuppressed patients [3] . Precautions to prevent spread of vaccinia include the use of occlusive bandages over the site, careful attention to dressing care, and meticulous hand hygiene. The low incidence of contact vaccinia in the recent civilian and military vaccination campaigns in the United States has provided reassurance regarding the very low risk of vaccinia transmission when proper bandaging and hand hygiene practices are used [5, 6] . There have been no reported cases of contact spread to date in the civilian campaign [5] . In the military experience, only 21 cases of contact vaccinia occurred over 306,673 person-months of contact [6] . Our data, which use viral culture information, provide additional support for these findings. NOTE. There were no significant differences between the 2 groups for any noted variable.
Before the recent campaign and our investigation, studies conducted on recombinant HIV-vaccinia virus vaccines had evaluated the infectivity of the vaccination lesions and the protection provided by standard dressings. In one trial, the vaccination site was covered by gauze and 2 occlusive bandages, and outer bandage surfaces were negative for vaccinia and no household or sexual contacts developed clinical or serologic evidence of vaccinia exposure [10] . In a similar trial, Graham et al. [8] , who used a single occlusive transparent polyurethane dressing over the site, recovered vaccinia from 12 (18.2%) of 66 cultures of samples from the dressing surface. The addition of a second occlusive dressing and a sterile gauze pad reduced the rate of positive dressing cultures to 3% (3 of 103 cultures).
Despite the supporting evidence from these studies, there has been continued skepticism about the protection conferred by occlusive bandages and meticulous infection-control practices. In a recent review article citing historical reports, Sepkowitz [4] commented that nosocomial vaccinia required "relatively minor contact with a source case" (p. 443). Many of the highlighted cases, however, resulted from contact with individuals who had disseminated complications from vaccination, such as eczema vaccinatum and generalized vacciniasituations with a greater degree of viral shedding and, thus, a higher likelihood of secondary transmission, a distinction not made in the review. Reflecting these concerns, some conclusions reached in this review have subsequently been questioned by Neff et al. [11] .
In our study, vaccinia was recovered from the external surface of the outer bandages in 5 of the 6 subjects during days 7-10 after inoculation. This is the usual time when local symptoms, such as pain and pruritus, reach their peak, and inadvertent touching of the site might be expected to occur. Vaccinated individuals should therefore use particular care to avoid manipulation of the inoculation site during the first weeks after vaccination. We did not see a statistically significant association between vaccinia recovery and the number of unscheduled bandage changes performed by the subjects, measures of high viral shedding, such as peak and mean lesion titers, and surrogate markers of a severe host immune response that may serve as a measure of vaccinia burden (e.g., fever and lymphadenopathy). However, the number of subjects with a positive dressing culture was only 6, limiting the statistical power to detect subtle differences between those with and without positive cultures.
There are a few limitations to our study. Subjects received a different smallpox vaccine (APSV) from the currently administered lyophilized vaccine (Dryvax; Wyeth Laboratories) used in the military and civilian campaigns. The degree of vaccinia shedding from vaccination pustules induced from these 2 vaccines has not been directly compared; however, both are derived from the same vaccinia strain. In this study, a systematic evaluation for secondary transmission was not performed, thus potentially limiting any conclusions regarding the risk of vaccinia transmission. However, autoinoculation of vaccinia, which occurred more than twice as often as secondary transmission in the recent military campaign (48 cases vs. 21 cases of secondary spread [6] ), also serves as a measure of transmission. In our investigation, surveillance for episodes of autoinoculation of vaccinia was performed, and autoinoculation of vaccinia did not occur. This suggests that there is a low risk of transmission from covered vaccination sites, but definitive conclusions on the risk of all types of vaccinia transmission cannot be made. There was also no comparison group to determine the rate of vaccinia transmission to the hands of individuals without bandages covering the vaccination site. Although this would allow direct comparison of the recovery of vaccinia from sites covered by occlusive bandages to the recovery from unbandaged sites, we were unable to perform such an investigation, because current US Centers for Disease Control and Prevention guidelines do not recommend leaving vaccination sites uncovered [7] .
The generalizability of our results to a broader population could be questioned, because subjects in our trial were monitored intensively, and meticulous dressing care and hand hygiene were emphasized on many occasions. Present plans for vaccinated civilians involve monitoring and education of vaccinees [12] , but not to the extent seen in this trial. Whether such differences lead to higher rates of recovery of vaccinia from site bandages requires additional study. Finally, this investigation only examined 1 type of vaccination site dressing. Other bandages, such as the gauze bandage currently used for vaccinated non-health care workers, may not be as protective as the occlusive bandages used in our study. A trial comparing vaccinia retrieval from sites covered by several bandage types is currently under way at our institution. With hope, this will provide additional contemporary data regarding the protection provided by vaccination-site bandages.
The reinstitution of smallpox vaccination has evoked many new questions about an old, nearly forgotten vaccine. Although experience is quite extensive, current vaccinia administration is being introduced into a very different environment, which has led many to question the vaccine's safety [4] . Although no infection-control measure can be absolutely effective, our study reinforces the recent civilian and military vaccination experience that intensive education and proper infection-control procedures limit the potential for secondary transmission of vaccinia from sites covered with 2 occlusive bandages. This will, we hope, allay many of the concerns regarding the risk of contact vaccinia and allow a wider acceptance of the vaccine.
